TSFAE08:	Subjects With Treatment-emergent Adverse Events (Excluding Serious Adverse Events) With Frequency =[5]% in [Any Treatment Group] by System Organ Class and Preferred Term; Safety Analysis Set (Study jjcs - core)					
 	Active Study Agent 	Active Study Agent 	Active Study Agent 	 	
System Organ Class 	Xanomeline High Dose 	Xanomeline Low Dose 	Combined 	Placebo 	
  Preferred Term, n (%) 	N=53 	N=73 	N=126 	N=59 	
Subjects with ≥1 AE 	47 (88.7%) 	54 (74.0%) 	101 (80.2%) 	34 (57.6%) 	
 	 	 	 	 	
General disorders and administration site conditions 	21 (39.6%) 	26 (35.6%) 	47 (37.3%) 	10 (16.9%) 	
APPLICATION SITE PRURITUS 	7 (13.2%) 	12 (16.4%) 	19 (15.1%) 	3 (5.1%) 	
APPLICATION SITE ERYTHEMA 	6 (11.3%) 	7 (9.6%) 	13 (10.3%) 	1 (1.7%) 	
APPLICATION SITE IRRITATION 	5 (9.4%) 	5 (6.8%) 	10 (7.9%) 	1 (1.7%) 	
APPLICATION SITE DERMATITIS 	1 (1.9%) 	4 (5.5%) 	5 (4.0%) 	3 (5.1%) 	
 	 	 	 	 	
Skin and subcutaneous tissue disorders 	25 (47.2%) 	21 (28.8%) 	46 (36.5%) 	10 (16.9%) 	
PRURITUS 	13 (24.5%) 	7 (9.6%) 	20 (15.9%) 	5 (8.5%) 	
ERYTHEMA 	5 (9.4%) 	4 (5.5%) 	9 (7.1%) 	2 (3.4%) 	
RASH 	3 (5.7%) 	6 (8.2%) 	9 (7.1%) 	3 (5.1%) 	
HYPERHIDROSIS 	5 (9.4%) 	1 (1.4%) 	6 (4.8%) 	0 	
SKIN IRRITATION 	3 (5.7%) 	3 (4.1%) 	6 (4.8%) 	1 (1.7%) 	
 	 	 	 	 	
Nervous system disorders 	13 (24.5%) 	11 (15.1%) 	24 (19.0%) 	2 (3.4%) 	
DIZZINESS 	6 (11.3%) 	6 (8.2%) 	12 (9.5%) 	0 	
HEADACHE 	4 (7.5%) 	0 	4 (3.2%) 	1 (1.7%) 	
 	 	 	 	 	
Cardiac disorders 	8 (15.1%) 	8 (11.0%) 	16 (12.7%) 	4 (6.8%) 	
SINUS BRADYCARDIA 	5 (9.4%) 	2 (2.7%) 	7 (5.6%) 	0 	
 	 	 	 	 	
Gastrointestinal disorders 	6 (11.3%) 	6 (8.2%) 	12 (9.5%) 	4 (6.8%) 	
NAUSEA 	3 (5.7%) 	2 (2.7%) 	5 (4.0%) 	0 	
DIARRHOEA 	0 	1 (1.4%) 	1 (0.8%) 	3 (5.1%) 	
 	 	 	 	 	
Respiratory, thoracic and mediastinal disorders 	5 (9.4%) 	5 (6.8%) 	10 (7.9%) 	4 (6.8%) 	
COUGH 	1 (1.9%) 	4 (5.5%) 	5 (4.0%) 	1 (1.7%) 	
NASAL CONGESTION 	3 (5.7%) 	0 	3 (2.4%) 	2 (3.4%) 	
 	 	 	 	 	
Infections and infestations 	4 (7.5%) 	4 (5.5%) 	8 (6.3%) 	11 (18.6%) 	
UPPER RESPIRATORY TRACT INFECTION 	1 (1.9%) 	0 	1 (0.8%) 	3 (5.1%) 	

Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. 	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Adverse events are coded using MedDRA version 26.0. 	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.